Oncogenic osteomalacia cured by removal of an organized hematoma

Endocrine Practice

Volumn 11, Issue 3, 2005, Pages 190-193

  Colt, Edward ^a   Gopan, Thottathil ^a   Chong, Hyun Suk ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; PARATHYROID HORMONE; PHOSPHATE;

ADULT; ARTICLE; BONE PAIN; CALCIUM BLOOD LEVEL; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DEPRESSION; DISEASE DURATION; DRUG USE; FEMALE; HEMATOMA; HIP; HISTOPATHOLOGY; HUMAN; HYPOPHOSPHATEMIA; LABORATORY TEST; MEDICAL LITERATURE; MUSCLE WEAKNESS; NEGRO; OBESITY; OSTEOMALACIA; PARANEOPLASTIC SYNDROME; PARATHYROID HORMONE BLOOD LEVEL; PHOSPHATE BLOOD LEVEL; PHYSICAL EXAMINATION; POSTOPERATIVE PERIOD; RETROSPECTIVE STUDY; STRENGTH; VITAMIN BLOOD LEVEL; ASTHMA; BLOOD; CHRONIC DISEASE;

ADULT; ASTHMA; CALCITRIOL; CHRONIC DISEASE; FEMALE; HEMATOMA; HUMANS; OBESITY; OSTEOMALACIA; PARATHYROID HORMONE; PHOSPHATES;

EID: 27744444023     PISSN: 1530891X     EISSN: None     Source Type: Journal    
DOI: 10.4158/EP.11.3.190     Document Type: Article

References (19)

1. Weidner N. Review and update: oncogenic osteomalacia-rickets. Ultrastruct Pathol. 1991;15:317-333.
2. Sundaram M, McCarthy EF. Oncogenic osteomalacia. Skeletal Radiol. 2000;29:117-124.
3. Ryan EA, Reiss E. Oncogenous osteomalacia: review of the world literature of 42 cases and report of two new cases. Am J Med. 1984;77:501-512.
4. Prader A, Illig R, Uehlinger E, Stalder G. Rickets following bone tumor [article in German]. Helv Paediatr Acta. 1959;14:554-565.
5. Drezner MK. Tumor-induced rickets and osteomalacia. In: Favus MJ, ed. Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 3rd ed. New York, NY: Lippincott-Raven, 1996: 319-325.
6. Nelson AE, Bligh RC, Mirams M, et al. Clinical case seminar: fibroblast growth factor 23; a new clinical marker for oncogenic osteomalacia. J Clin Endocrinol Metab. 2003;88:4088-4094.
7. Wilkins GE, Granleese S, Hegele RG, Holden J, Anderson DW, Bondy GP. Oncogenic osteomalacia: evidence of a humoral phosphaturic factor. J Clin Endocrinol Metab. 1995;80:1628-1634.
8. Folpe AL, Fanburg-Smith JC, Billings SD, et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol. 2004;28:1-30.
9. Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med. 2003;348:1656-1663.
10. Berndt T, Craig TA, Bowe AE, et al. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J Clin Invest. 2003;112:785-794.
11. De Beur SM, Finnegan RB, Vassiliadis J, et al. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res. 2002;17:1102-1110.
12. Crouzet J, Mimoune H, Beraneck L, Juan LH. Hypophosphatemic osteomalacia with plantar neurilemoma: a review of literature (100 cases). Rev Rheum Engl Ed. 1995; 62:463-466.
13. Weidner N, Santa Cruz D. Phosphaturic mesenchymal tumors: a polymorphous group causing osteomalacia or rickets. Cancer. 1987;59:1442-1454.
14. Angele MK, Knoferi MW, Ayala A, et al. Trauma-hemorrhage delays wound healing potentially by increasing pro-inflammatory cytokines at the wound site. Surgery. 1999;126:279-285.
15. Jaiswal M, LaRussi NF, Burgart LJ, Gores GJ. Inflammatory cytokines induce DNA damage and inhibit DNA repair in cholangiocarcinoma cells by a nitric oxide-dependent mechanism. Cancer Res. 2000;60:184-190.
16. Hu SI, Carozza M, Klein M, Nantermet P, Luk D, Crowl RM. Human HtrA, an evolutionary conserved serine protease identified as a differentially expressed gene product in osteoarthritic cartilage. J Biol Chem. 1998;273: 34406-34412.
17. Quarles LD, Drezner MK. Pathophysiology of X-linked hypophosphatemia, tumor-induced osteomalacia, and autosomal dominant hypophosphatemia: a perPHEXing problem. J Clin Endocrinol Metab. 2001;86:494-496.
18. Econs MJ, McEnery PT. Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab. 1997;82:674-681.
19. HYP Consortium. A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet. 1995;11:130-136.